Tag Archives: 2013 BIO International Convention

Natalie Ng wins the International BioGENEius Challenge

Natalie Ng

Today, Cupertino Junior Natalie Ng won the International BioGENEius Challenge, the premier competition for high school students that recognizes outstanding research in biotechnology. Natalie’s research in breast cancer and biomarkers helped her stand out from the 13 other finalists from across the U.S., Canada and Australia competing for the Challenge’s top prize, a $7,500 cash award. The winner was named during the 2013 BIO International Convention’s keynote luncheon.  The International BioGENEius Challenges is one of Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Getting to Know Women in Bio

Getting to Know Women in Bio

We caught up with Women In Bio’s President, Phyllis Dillinger, to learn more about the group’s philosophy, agenda, programming and networking events Tell me about your organization and why it was founded. A few smart, entrepreneurial women in greater Washington, D.C. started Women In Bio in 2002 to meet like-minded women in the biosciences who could provide support for building their businesses. Since then, we’ve expanded our mission to include mentoring, networking and development opportunities Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Panelists Talk GMOs at BIO Convention

Panelists Talk GMOs at BIO Convention

On Monday at BIO’s International Convention, the U.S. Farmers & Ranchers Alliance (USFRA®) hosted The Food Dialogues: Chicago, bringing together farmers, industry experts, scientists, pundits, media and consumers with varying perspectives. The panel called “The Straight Story on Biotech In Agriculture: The Media and its Impact on Consumers” featured moderator Ron Insana, CNCB and financial industry expert. Opening remarks from Congressman Rodney Davis (Ill.) and Robert Flider, director of Illinois Department of Agriculture set the Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Q & A with Eli Lilly’s Eric Siemers

Q+A with Eli Lillys Eric Siemers

In October 2012, Eli Lilly and Company released results of its Expedition trials, two Phase 3, double-blind, placebo-controlled studies of the anti-amyloid antibody solanezumab, in patients with mild-to-moderate Alzheimer’s disease. Although cognitive decline was slowed in patients with early stage disease in one trial, and there were also positive signs from the other trial, those findings were not statistically significant. But a secondary analysis conducted independently by a panel of academic researchers pooled data from Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

New Challenges in the Fast Changing Landscape of Bioinformatics

Adina

The world of DNA sequencing and bioinformatics has evolved at a staggering pace. In 2009, the biggest problem for researchers was creating an efficient solution for sequencing DNA. At that time, sequencing cost of $100,000 for a single human and took 30 days of chemical processing to produce the raw sequencing output. In four years, DNA sequencing technology has advanced rapidly, outpacing even Moore’s Law. Today, researchers can sequence a whole human genome for about Read More >

Health  |  1 Comment  |  Email This Post
Tags: , , , , , , , , ,